Tower Research Capital LLC TRC Acquires 17,042 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Tower Research Capital LLC TRC grew its holdings in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 128.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,340 shares of the company’s stock after acquiring an additional 17,042 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Atea Pharmaceuticals were worth $93,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of AVIR. Advisor Group Holdings Inc. grew its stake in Atea Pharmaceuticals by 78.8% in the 1st quarter. Advisor Group Holdings Inc. now owns 4,070 shares of the company’s stock worth $28,000 after buying an additional 1,794 shares in the last quarter. Lazard Asset Management LLC grew its position in Atea Pharmaceuticals by 26.7% in the first quarter. Lazard Asset Management LLC now owns 10,908 shares of the company’s stock worth $78,000 after acquiring an additional 2,298 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Atea Pharmaceuticals by 16.4% in the second quarter. Envestnet Asset Management Inc. now owns 17,107 shares of the company’s stock valued at $121,000 after acquiring an additional 2,410 shares during the last quarter. Royal Bank of Canada lifted its stake in Atea Pharmaceuticals by 123.6% during the third quarter. Royal Bank of Canada now owns 4,536 shares of the company’s stock worth $26,000 after purchasing an additional 2,507 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its stake in Atea Pharmaceuticals by 93.3% during the second quarter. Osaic Holdings Inc. now owns 7,154 shares of the company’s stock worth $27,000 after purchasing an additional 3,453 shares during the last quarter. 86.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CAO Wayne Foster sold 12,477 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $3.84, for a total value of $47,911.68. Following the completion of the sale, the chief accounting officer now owns 20,857 shares of the company’s stock, valued at approximately $80,090.88. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Atea Pharmaceuticals news, CEO Jean-Pierre Sommadossi sold 56,910 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $3.85, for a total value of $219,103.50. Following the transaction, the chief executive officer now owns 116,557 shares in the company, valued at $448,744.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Wayne Foster sold 12,477 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $3.84, for a total transaction of $47,911.68. Following the sale, the chief accounting officer now owns 20,857 shares of the company’s stock, valued at $80,090.88. The disclosure for this sale can be found here. Insiders sold 85,230 shares of company stock valued at $327,852 over the last three months. Insiders own 14.50% of the company’s stock.

Atea Pharmaceuticals Price Performance

Shares of Atea Pharmaceuticals stock traded down $0.04 during trading on Friday, hitting $3.81. 137,985 shares of the stock traded hands, compared to its average volume of 367,328. Atea Pharmaceuticals, Inc. has a 52 week low of $2.77 and a 52 week high of $5.19. The firm’s fifty day moving average is $4.08 and its 200-day moving average is $3.46.

Atea Pharmaceuticals (NASDAQ:AVIR) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Sell-side analysts forecast that Atea Pharmaceuticals, Inc. will post -2.76 EPS for the current fiscal year.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.